Kent Osborne, MD, of Baylor College of Medicine, commented on Dr. Slamon's statement. "I will take this conclusion one step further," he said. "Now there is a question of whether any kind of chemotherapy offers anything to a truly endocrine-responsive tumor. As your curves with all these chemotherapies come together, one wonders if the chemotherapy is adding nothing, and all we are seeing is the effect of Herceptin."
Dr. Slamon responded, "This question is right on target, and is one that we need to ask and answer. I think it will be a challenge to enroll patients in such a trial, but this is the direction in which we now need to go."